Wolfgang E. Berdel

33 Albert Schweitzer Street
Muenster, NW 48149, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 270 publications

Transport of cytotoxic cyanine dyes coupled to siRNA into hematopoietic cancer cells with CD20-, CD22- or CD33-targeting ELART nanocarriers.

Transport of cytotoxic cyanine dyes coupled to siRNA into hematopoietic cancer cells with CD20-, CD22- or CD33-targeting ELART nanocarriers.

Journal: Scientific reports
Published: May 13, 2026

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Journal: Nature medicine
Published: January 07, 2026

Reduce bureaucracy in clinical trials now.

Reduce bureaucracy in clinical trials now.

Journal: Nature medicine
Published: January 06, 2026

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Journal: Scientific reports
Published: September 27, 2025

Centralised ethics review of clinical trials in a public health emergency in the EU.

Centralised ethics review of clinical trials in a public health emergency in the EU.

Journal: Lancet (London, England)
Published: September 27, 2025

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Journal: American journal of hematology
Published: August 18, 2025

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Journal: Leukemia
Published: August 15, 2025

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Journal: Blood neoplasia
Published: June 09, 2025

Photodynamic ROS inducers delivered via electrostatic antibody targeted (ELART) nanocarriers incorporate into tumour cells and inhibit colony growth.

Photodynamic ROS inducers delivered via electrostatic antibody targeted (ELART) nanocarriers incorporate into tumour cells and inhibit colony growth.

Journal: Chemical communications (Cambridge, England)
Published: May 06, 2025

Clonal hematopoiesis in AML long-term survivors: Risk factors and clinical consequences.

Clonal hematopoiesis in AML long-term survivors: Risk factors and clinical consequences.

Journal: HemaSphere
Published: March 11, 2025

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Journal: Blood
Published: February 07, 2025

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).

Journal: Leukemia
Published: January 28, 2025
Showing 1-12 of 270

Last Updated: 09/26/2026